India's Ranbaxy gets US FDA nod to manufacture, market generic of GSK's Ceftin
BANGALORE, Feb. 6, 2008 (Thomson Financial delivered by Newstex) -- India's Ranbaxy Laboratories Ltd said its US unit has received US FDA approval to manufacture and market the generic version of GlaxoSmithKline PLC's (NYSE:GSK) paediatric anti-bacterial drug Ceftin, Cefuroxime Axetil, for oral suspension in the 125mg/5ml and 250mg/5ml dosage form.
The pharma major said the total annual market sales for Cefuroxime Axetil Suspension were 28.7 mln usd as per IMS Health (NYSE:RX) data, December 2007.
Jim Meehan, vice president of sales and distribution for Ranbaxy's US unit, said: 'Ranbaxy is pleased to receive this approval for Cefuroxime Axetil Suspension that now allows us to be the only generic company to offer both dosage forms for a product that is highly prescribed.'
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication
or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly
prohibited without the prior written consent of Thomson
February 06, 2008